In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

Each novel vaccine candidate needs to be evaluated for safety, immunogenicity, and
protective efficacy in humans before it is licensed for use. After initial safety evaluation in …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …

Background Controlled infection studies in malaria-naive adults suggest increased vaccine
efficacy for fractional-dose versus full-dose regimens of RTS, S/AS01. We report first results …

The development of vaccines plays a vital role in the effective control of several fatal
diseases. However, effective prophylactic and therapeutic vaccines have yet to be …

Background Results from a previous phase 3 study showed efficacy of the RTS, S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …